Reading fine print, insurers question studies of drugs

Article Abstract:

Watchdogs that work for Medicaid Programs, insurers and nonprofit organizations are studying the advertising of pharmaceutical companies, debunking advertising spin on new medications. By studying the clinical trials closely they are able to help the consumer understand what the research is really saying.

United States, Science & research, Medical Service and Health Insurance, Research, Health insurance industry, Watchdogs

---

Allergan bets on aesthetic medicine: Botox maker plans ad push to position itself as leader; a direct-to-consumer tack

Article Abstract:

In a bid to gain market share, Allergan Inc. plans to spend more money on advertising such aesthetic medicine products as breast implants and facial-rejuvenation treatments . The goal is to make such products as acceptable to consumers as Botox.

Pharmaceutical Preparation Manufacturing, Market share, Public affairs, Dermatological Preparations, Skin Treatment Preparations, Public opinion, Breast implants, Company market share, Dermatologic agents, Dermatology, Allergan Inc., AGN, Botox (Medication), Breast prosthesis

---

Similar abstracts:

• Abstracts: Pfizer posts loss of 3.12 billion euros on acquisition. Pfizer nears a deal to acquire Angiosyn, pad eye-drug roster
• Abstracts: Ahold's net increases 76% on higher sales, lower interest. Supermarket company to post its first-half results Nov. 7

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.